aTyr Pharma, Inc. (LIFE) Stock Rating Lowered by Zacks Investment Research
aTyr Pharma, Inc. (NASDAQ:LIFE) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.
According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “
Several other equities research analysts also recently weighed in on the stock. ValuEngine raised shares of aTyr Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, July 8th. Piper Jaffray Companies started coverage on shares of aTyr Pharma in a research report on Thursday, September 7th. They set an “overweight” rating and a $7.00 price target for the company. Finally, BMO Capital Markets set a $4.00 price target on shares of aTyr Pharma and gave the company a “hold” rating in a research report on Tuesday, August 15th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company’s stock. aTyr Pharma presently has an average rating of “Hold” and a consensus price target of $4.62.
aTyr Pharma (NASDAQ:LIFE) opened at 5.15 on Wednesday. The stock has a 50 day moving average price of $4.69 and a 200 day moving average price of $4.69. The company’s market capitalization is $122.77 million. aTyr Pharma has a 12-month low of $2.10 and a 12-month high of $6.50.
aTyr Pharma (NASDAQ:LIFE) last announced its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.51) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.57) by $0.06. On average, analysts expect that aTyr Pharma will post ($2.18) EPS for the current year.
In other news, Director Paul Schimmel purchased 94,336 shares of aTyr Pharma stock in a transaction that occurred on Thursday, August 31st. The stock was bought at an average price of $2.65 per share, with a total value of $249,990.40. Following the completion of the transaction, the director now directly owns 40,440 shares of the company’s stock, valued at $107,166. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO John Mendlein bought 37,736 shares of the business’s stock in a transaction on Thursday, August 31st. The stock was bought at an average cost of $2.65 per share, with a total value of $100,000.40. The disclosure for this purchase can be found here. 33.30% of the stock is owned by company insiders.
An institutional investor recently raised its position in aTyr Pharma stock. Renaissance Technologies LLC grew its holdings in shares of aTyr Pharma, Inc. (NASDAQ:LIFE) by 1.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 38,800 shares of the biotechnology company’s stock after acquiring an additional 700 shares during the period. Renaissance Technologies LLC owned about 0.16% of aTyr Pharma worth $136,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 46.66% of the stock is owned by institutional investors.
aTyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Stock Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related stocks with our FREE daily email newsletter.